Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.

Gold, Ralf;Kappos, Ludwig;Arnold, Douglas L;Bar-Or, Amit;Sindic, Christian;et.al.
(2012) New England Journal of Medicine — Vol. 367, n° 12, p. 1098-1107 (2012)

Files

Placebo-controlledphase3studyoforalbg12forrelapsing.pdf
  • Open Access
  • Adobe PDF
  • 514.74 KB
Download

Details

Authors
  • Gold, Ralf
    Author
  • Kappos, Ludwig
    Author
  • Arnold, Douglas L
    Author
  • Bar-Or, Amit
    Author
  • Sindic, ChristianUCLouvain
    Author
Show more
Abstract
In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI. (Funded by Biogen Idec; DEFINE ClinicalTrials.gov number, NCT00420212.).
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., Dawson, K. T., & Sindic, C. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. New England Journal of Medicine, 367(12), 1098-1107. https://doi.org/10.1056/NEJMoa1114287 (Original work published 2012)